Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
